Dendreon Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Seattle WA United States (1992)
Status: Acquired by Bausch Health Companies (2015)

Organization Overview

First Clinical Trial
1999
NCT00005947
First Marketed Drug
2010
sipuleucel-t (Provenge)
First NDA Approval
2010
sipuleucel-t (Provenge)
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dendreon | Dendreon Corp. | Dendreon Pharmaceuticals LLC

Active Ingredients

Marketed Drugs (1)

sipuleucel-t (Provenge) (2010 NDA)

Drugs in Phase 3 Trials (1)

sipuleucel-t (Provenge) (15 trials)

Drugs in Phase 2 Trials (4)

abiraterone (zytiga) (1 trial)

dn24-02 (1 trial)

enzalutamide (xtandi) (1 trial)

leuprolide (lupron) (1 trial)

Drugs in Phase 1 Trials (2)

atezolizumab (Tecentriq) (1 trial)

d-3263 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 7